Literature DB >> 3422207

In vitro and in vivo degradation of human gastrin by endopeptidase 24.11.

M Deschodt-Lanckman1, S Pauwels, T Najdovski, R Dimaline, G J Dockray.   

Abstract

The degradation of human unsulfated heptadecapeptide gastrin (G-17) by human kidney endopeptidase 24.11 has been studied in vitro, and some of the products of degradation have been identified in plasma after in vivo infusion of G-17. The enzyme cleaved G-17 at four peptide bonds: Trp4Leu5, Ala11Tyr12, Gly13Trp14, and Asp16Phe17. The cleavage at Gly-Trp was rapid and 1-13 G-17 was an important intermediate. All the products of cleavage of synthetic 1-13 G-17 were also found after degradation of intact G-17. When normal human volunteers received infusions of G-17, there appeared in their blood peptides with the properties of 1-11, 1-13, 1-16, and 5-17 G-17 on the basis of immunochemical and high-performance liquid chromatographic properties. These observations provide evidence that endopeptidase 24.11 is involved in gastrin metabolism in humans, and may be responsible for the generation of G-17 fragments in the peripheral circulation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3422207     DOI: 10.1016/0016-5085(88)90244-2

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  9 in total

1.  [99mTc]Tc-DGA1, a Promising CCK2R-Antagonist-Based Tracer for Tumor Diagnosis with Single-Photon Emission Computed Tomography.

Authors:  Aikaterini Kaloudi; Panagiotis Kanellopoulos; Thorsten Radolf; Oleg G Chepurny; Maritina Rouchota; George Loudos; Fritz Andreae; George G Holz; Berthold Artur Nock; Theodosia Maina
Journal:  Mol Pharm       Date:  2020-07-07       Impact factor: 4.939

2.  Respective roles of kallikrein and endopeptidase 24.11 in the metabolic pathway of atrial natriuretic peptide in the rat.

Authors:  Y Vanneste; S Pauwels; L Lambotte; A Michel; R Dimaline; M Deschodt-Lanckman
Journal:  Biochem J       Date:  1990-08-01       Impact factor: 3.857

3.  Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice.

Authors:  Nathalie Esser; Christine Schmidt; Breanne M Barrow; Laura Cronic; Daryl J Hackney; Stephen M Mongovin; Meghan F Hogan; Andrew T Templin; Joseph J Castillo; Rebecca L Hull; Sakeneh Zraika
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-06       Impact factor: 6.055

4.  Novel activity of angiotensin-converting enzyme. Hydrolysis of cholecystokinin and gastrin analogues with release of the amidated C-terminal dipeptide.

Authors:  P Dubreuil; P Fulcrand; M Rodriguez; H Fulcrand; J Laur; J Martinez
Journal:  Biochem J       Date:  1989-08-15       Impact factor: 3.857

5.  Hydrolysis of alpha-human atrial natriuretic peptide in vitro by human kidney membranes and purified endopeptidase-24.11. Evidence for a novel cleavage site.

Authors:  Y Vanneste; A Michel; R Dimaline; T Najdovski; M Deschodt-Lanckman
Journal:  Biochem J       Date:  1988-09-01       Impact factor: 3.857

6.  Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma.

Authors:  Ulrik Ø Andersen; Dijana Terzic; Nicolai Jacob Wewer Albrechtsen; Peter Dall Mark; Peter Plomgaard; Jens F Rehfeld; Finn Gustafsson; Jens P Goetze
Journal:  Endocr Connect       Date:  2020-05       Impact factor: 3.335

7.  Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [(111)In-DOTA]MG11-first estimates for clinical translation.

Authors:  Aikaterini Kaloudi; Berthold A Nock; Emmanouil Lymperis; Roelf Valkema; Eric P Krenning; Marion de Jong; Theodosia Maina
Journal:  EJNMMI Res       Date:  2016-02-16       Impact factor: 3.138

8.  Initial In Vitro and In Vivo Evaluation of a Novel CCK2R Targeting Peptide Analog Labeled with Lutetium-177.

Authors:  Anton Amadeus Hörmann; Maximilian Klingler; Maliheh Rezaeianpour; Nikolas Hörmann; Ronald Gust; Soraya Shahhosseini; Elisabeth von Guggenberg
Journal:  Molecules       Date:  2020-10-08       Impact factor: 4.411

9.  Nonpeptidic Z360-Analogs Tagged with Trivalent Radiometals as Anti-CCK2R Cancer Theranostic Agents: A Preclinical Study.

Authors:  Berthold A Nock; Panagiotis Kanellopoulos; Oleg G Chepurny; Maritina Rouchota; George Loudos; George G Holz; Eric P Krenning; Theodosia Maina
Journal:  Pharmaceutics       Date:  2022-03-18       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.